<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02255032</url>
  </required_header>
  <id_info>
    <org_study_id>CLS1001-201</org_study_id>
    <nct_id>NCT02255032</nct_id>
  </id_info>
  <brief_title>Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis</brief_title>
  <acronym>DOGWOOD</acronym>
  <official_title>A Randomized, Masked, Multicenter Study to Assess the Safety and Efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Following Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clearside Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clearside Biomedical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the safety and efficacy of triamcinolone acetonide, CLS-TA,
      in subjects with macular edema following non-infectious uveitis. A single suprachoroidal
      injection of one of two doses of CLS-TA will each be evaluated in subjects with macular edema
      following non-infectious uveitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, masked, multicenter study to assess the safety and efficacy of
      two different doses of CLS-TA in the treatment of subjects with macular edema following
      non-infectious uveitis. Each subject will receive a single suprachoroidal injection of
      CLS-TA.

      The subjects enrolled in this study will be chosen from subjects with macular edema following
      non-infectious uveitis. A single injection will be administered via the Clearside
      microinjector into the suprachoroidal space. The dose injected will either be 4 mg or 0.8 mg
      of CLS-TA in a total volume of 100 μL. The dose they receive will depend on what their
      randomization code dictates.

      Subjects will be monitored for safety and efficacy for approximately 8 weeks following
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in central subfield thickness, measured using optical coherence tomography, after treatment with CLS-TA in subjects with macular edema following uveitis</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Uveitis</condition>
  <condition>Macular Edema</condition>
  <condition>Uveitis, Posterior</condition>
  <condition>Uveitis, Anterior</condition>
  <condition>Panuveitis</condition>
  <condition>Uveitis, Intermediate</condition>
  <arm_group>
    <arm_group_label>4 mg CLS-TA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.8 mg CLS-TA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single unilateral, suprachoroidal injection of 8 mg/mL (0.8 mg in 100 µL) of CLS-TA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 mg CLS-TA</intervention_name>
    <description>4 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)</description>
    <arm_group_label>4 mg CLS-TA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.8 mg CLS-TA</intervention_name>
    <description>0.8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)</description>
    <arm_group_label>0.8 mg CLS-TA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of noninfectious uveitis

          -  diagnosis of macular edema associated with noninfectious uveitis

        Exclusion Criteria:

          -  any ocular trauma within the immediate 6 months prior to treatment

          -  any photocoagulation or cryotherapy in the 6 months prior to treatment

          -  any IVT injection of anti-VEGF treatment in the 2 months prior to treatment

          -  any eye diseases other than uveitis and ME that could compromise central visual acuity

          -  any previous suprachoroidal injection of triamcinolone acetonide in the study eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Noronha, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clearside Biomedical, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2014</study_first_posted>
  <disposition_first_submitted>June 28, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>June 28, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 5, 2017</disposition_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uveitis</keyword>
  <keyword>macular edema</keyword>
  <keyword>UME</keyword>
  <keyword>posterior uveitis</keyword>
  <keyword>anterior uveitis</keyword>
  <keyword>panuveitis</keyword>
  <keyword>intermediate uveitis</keyword>
  <keyword>noninfectious uveitis</keyword>
  <keyword>triamcinolone acetonide</keyword>
  <keyword>suprachoroidal space</keyword>
  <keyword>injection</keyword>
  <keyword>microneedle</keyword>
  <keyword>intravitreal injection</keyword>
  <keyword>corticosteroid</keyword>
  <keyword>CME</keyword>
  <keyword>choroid</keyword>
  <keyword>retina</keyword>
  <keyword>microinjection</keyword>
  <keyword>SCS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Panuveitis</mesh_term>
    <mesh_term>Uveitis, Posterior</mesh_term>
    <mesh_term>Uveitis, Intermediate</mesh_term>
    <mesh_term>Pars Planitis</mesh_term>
    <mesh_term>Uveitis, Anterior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

